Keywords
How to Cite
Abstract
Study question: Is there an association between BMI >25 kg/m2, ovarian function, ovarian reserve, and/or reproductive outcomes in women undergoing assisted fertility treatments? What is already known: There is an association between fertility loss and elevated basal FSH and decreased AMH levels. Obesity and overweight could be associated with changes in the concentrations of these hormones generating suboptimal results in ART. Study design: Cross-sectional, analytical study. Materials and Methods: The study included 23 women aged 25 to 38 with a BMI > 25 kg/m2 and 26 women of the same age range with a BMI < 25 kg/ m2; all without male factor associated to their infertility diagnosis, who underwent ART at HAVVA Clinic in Paraná, Entre Ríos; between January 2022 and June 2023. The values of AMH (ng/ml), basal FSH (UI/L) were analyzed as indicators of ovarian function and reserve, and the % of fertilization and % of blastocyst formation were were considered as indicators of ART efficacy. The association of these parameters with BMI was also investigated. Main results:On average, patients exhibited normal values for AMH and basal FSH (mean: 2.2 ng/ml and 6.99 IU/L, respectively). While no association was observed between BMI > 25 kg/m2 and the various analyzed parameters, it was noted that this population showed fertilization and blastocyst formation percentage values below the expected percentages to consider the treatment as optimal (78.17% and 47.83%, respectively). No correlation was observed between the BMI and the values of the parameters analyzed in our cohort of women. Limitations: The main limitations of this study include the small sample size, the lack of consideration of other predictors of ovarian failure and the only use of BMI >25 kg/m2 as an indicator of overweight or obesity, without considering the influence of factors like the percentage of muscle mass. Wider implications of the findings: The results observed here highlight the need for a multidisciplinary approach with therapists and nutritionists as a strategy in order to optimize the results obtained during fertilization treatments.
References
Vural B, Cakiroglu Y, Vural F, Filiz S. Hormonal and functional biomarkers in ovarian response. Arch Gynecol Obstet. 2014;289(6):1355-61.
Damario MA. General aspects of fertility and infertility. Methods Mol Biol. 2014;1154:3-23.
Buratini J, Dellaqua TT, Dal Canto M, La Marca A, Carone D, Mignini Renzini M, Webb R. The putative roles of FSH and AMH in the regulation of oocyte developmental competence: from fertility prognosis to mechanisms underlying age-related subfertility. Hum Reprod Update. 2022;28(2):232-254.
Gözükara İ, Yılmaz N, Ceran MU, Atalay E, Kahyaoğlu İ, Gülerman HC, Engin-Üstün Y. The role of FSH to AMH ratio in poor prognosis patients undergoing ICSI cycle. J Turk Ger Gynecol Assoc. 2022;23(3):184-189.
Kaltsas A, Zikopoulos A, Moustakli E, Zachariou A, Tsirka G, Tsiampali C, Palapela N, Sofikitis N, Dimitriadis F. The Silent Threat to Women’s Fertility: Uncovering the Devastating Effects of Oxidative Stress. Antioxidants (Basel). 2023 Jul;12(8):1490.
Macaluso M, Wright-Schnapp TJ, Chandra A, Johnson R, Satterwhite CL, Pulver A, Berman SM, Wang RY, Farr SL, Pollack LA. A public health focus on infertility prevention, detection, and management. Fertil Steril. 2010;93(1):1-10.
Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review. JAMA. 2021;326(1):65-76.
Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity’s impact. Fertil Steril. 2017;107(4):840-847.
Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. Reprod Biol Endocrinol. 2018;16(1):22.
Marinelli S, Napoletano G, Straccamore M, Basile G. Female obesity and infertility: outcomes and regulatory guidance. Acta Biomed. 2022;93(4):e2022278.
Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction. 2010;140(3):347-64.
Zain MM, Norman RJ. Impact of obesity on female fertility and fertility treatment. Womens Health (Lond). 2008;4(2):183-94.
Ozekinci M, Seven A, Olgan S, Sakinci M, Keskin U, Akar ME, Ceyhan ST, Ergun A. Does obesity have detrimental effects on IVF treatment outcomes? BMC Womens Health. 2015;15:61.
Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. Obstet Gynecol. 2011;118(1):63-70.
Tamer Erel C, Senturk LM. The impact of body mass index on assisted reproduction. Curr Opin Obstet Gynecol. 2009;21(3):228-35.
Sciorio R, Bellaminutti S, Tramontano L, Esteves SC. Impact of obesity on medically assisted reproductive treatments. Zygote. 2022;30(4):431-439.
Andreu A, Casals G, Vinagre I, Flores L. Obesity management in women of reproductive age. Endocrinol Diabetes Nutr (Engl Ed). 2023;70 Suppl 1:85-94.
Donini LM, Busetto L, Bischoff SC, et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15(3):321-335.
Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019;92:61-70.
Smith KB, Smith MS. Obesity Statistics. Prim Care. 2016;43(1):121-35, ix.
https://www.who.int/news-room/factsheets/detail/obesity-and-overweight.
ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod Biomed Online. 2017;35(5):494-510.
Pinborg A, Gaarslev C, Hougaard CO, Nyboe Andersen A, Andersen PK, Boivin J, et al. Influence of female bodyweight on IVF outcome: a longitudinal multicentre cohort study of 487 infertile couples. Reprod Biomed Online. 2011;23(4):490–9.
Moragianni VA, Jones SM, Ryley DA. The effect of body mass index on the outcomes of first assisted reproductive technology cycles. Fertil Steril. 2012;98(1):102–8.
Sessions-Bresnahan DR, Schauer KL, Heuberger AL, Carnevale EM. Effect of Obesity on the Preovulatory Follicle and Lipid Fingerprint of Equine Oocytes. Biol Reprod. 2016;94(1):15.
Malhotra N, Bahadur A, Singh N, Kalaivani M, Mittal S. Does obesity compromise ovarian reserve markers? A clinician’s perspective. Arch Gynecol Obstet. 2013;287(1):161-6.
Moslehi N, Shab-Bidar S, Ramezani Tehrani F, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta- analysis. Menopause. 2018;25(9):1046- 1055.
Gorkem U, Kucukler FK, Togrul C, Gungor T. Anti-Müllerian hormone exhibits a great variation in infertile women with different ovarian reserve patterns. Aust N Z J Obstet Gynaecol. 2017;57(4):464-468.
Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertil Steril. 2011;95(7):2364-8.
Luke B, Brown MB, Stern JE, Missmer SA, Fujimoto VY, Leach R; SART Writing Group. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum Reprod 2011;26(1):245–252.
García-Ferreyra J, Carpio J, Zambrano M, Valdivieso-Mejía P, Valdivieso-Rivera P. Overweight and obesity significantly reduce pregnancy, implantation, and live birth rates in women undergoing In Vitro Fertilization procedures. JBRA Assist Reprod. 2021;25(3):394-402.
Sarais V, Pagliardini L, Rebonato G, Papaleo E, Candiani M, Viganò P. A Comprehensive Analysis of Body Mass Index Effect on in Vitro Fertilization Outcomes. Nutrients. 2016;8(3):109.
Amiri M, Ramezani TF. Potential Adverse Effects of Female and Male Obesity on Fertility: A narrative Review. Int J Endocrinol Metab. 2020;18(3):e101776.